MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Aβ

Cara J. Westmark, Pamela R. Westmark, James S. Malter

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Metabotropic glutamate receptor 5 (mGluR5) regulates the translation of amyloid precursor protein (APP) mRNA. Under resting conditions, mRNA is bound to and translationally repressed by the fragile X mental retardation protein (FMRP). Upon group 1 mGluR activation, FMRP dissociates from the mRNA and translation ensues. APP levels are elevated in the dendrites of primary neuronal cultures as well as in synaptoneurosomes (SN) prepared from embryonic and juvenile fmr-1 knockout (KO) mice, respectively. In order to study the effects of APP and its proteolytic product Aβ on Fragile X syndrome (FXS) phenotypes, we created a novel mouse model (FRAXAD) that over-expresses human APPSwe/Aβ in an fmr-1 KO background. Herein, we assess (1) human APPSwe and Aβ levels as a function of age in FRAXAD mice, and (2) seizure susceptibility to pentylenetetrazol (PTZ) after mGluR5 blockade. PTZ-induced seizure severity is decreased in FRAXAD mice pre-treated with the mGluR5 antagonist MPEP. These data suggest that Aβ contributes to seizure incidence and may be an appropriate therapeutic target to lessen seizure pathology in FXS, Alzheimer's disease (AD) and Down syndrome (DS) patients.

Original languageEnglish (US)
Pages (from-to)56-68
Number of pages13
JournalInternational Journal of Clinical and Experimental Pathology
Volume3
Issue number1
StatePublished - 2010

Fingerprint

Knockout Mice
Amyloid beta-Protein Precursor
Seizures
Fragile X Mental Retardation Protein
Metabotropic Glutamate 5 Receptor
Fragile X Syndrome
Pentylenetetrazole
Alzheimer Disease
Excitatory Amino Acid Antagonists
Messenger RNA
Metabotropic Glutamate Receptors
Protein Biosynthesis
Dendrites
Down Syndrome
Pathology
Phenotype
Incidence
Therapeutics

Keywords

  • β-amyloid
  • APP
  • FMRP
  • FRAXAD
  • PTZ
  • Seizure
  • Tg2576

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Aβ. / Westmark, Cara J.; Westmark, Pamela R.; Malter, James S.

In: International Journal of Clinical and Experimental Pathology, Vol. 3, No. 1, 2010, p. 56-68.

Research output: Contribution to journalArticle

@article{b1da517627474d2590991566f7871c41,
title = "MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Aβ",
abstract = "Metabotropic glutamate receptor 5 (mGluR5) regulates the translation of amyloid precursor protein (APP) mRNA. Under resting conditions, mRNA is bound to and translationally repressed by the fragile X mental retardation protein (FMRP). Upon group 1 mGluR activation, FMRP dissociates from the mRNA and translation ensues. APP levels are elevated in the dendrites of primary neuronal cultures as well as in synaptoneurosomes (SN) prepared from embryonic and juvenile fmr-1 knockout (KO) mice, respectively. In order to study the effects of APP and its proteolytic product Aβ on Fragile X syndrome (FXS) phenotypes, we created a novel mouse model (FRAXAD) that over-expresses human APPSwe/Aβ in an fmr-1 KO background. Herein, we assess (1) human APPSwe and Aβ levels as a function of age in FRAXAD mice, and (2) seizure susceptibility to pentylenetetrazol (PTZ) after mGluR5 blockade. PTZ-induced seizure severity is decreased in FRAXAD mice pre-treated with the mGluR5 antagonist MPEP. These data suggest that Aβ contributes to seizure incidence and may be an appropriate therapeutic target to lessen seizure pathology in FXS, Alzheimer's disease (AD) and Down syndrome (DS) patients.",
keywords = "β-amyloid, APP, FMRP, FRAXAD, PTZ, Seizure, Tg2576",
author = "Westmark, {Cara J.} and Westmark, {Pamela R.} and Malter, {James S.}",
year = "2010",
language = "English (US)",
volume = "3",
pages = "56--68",
journal = "International Journal of Clinical and Experimental Pathology",
issn = "1936-2625",
publisher = "e-Century Publishing Corporation",
number = "1",

}

TY - JOUR

T1 - MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Aβ

AU - Westmark, Cara J.

AU - Westmark, Pamela R.

AU - Malter, James S.

PY - 2010

Y1 - 2010

N2 - Metabotropic glutamate receptor 5 (mGluR5) regulates the translation of amyloid precursor protein (APP) mRNA. Under resting conditions, mRNA is bound to and translationally repressed by the fragile X mental retardation protein (FMRP). Upon group 1 mGluR activation, FMRP dissociates from the mRNA and translation ensues. APP levels are elevated in the dendrites of primary neuronal cultures as well as in synaptoneurosomes (SN) prepared from embryonic and juvenile fmr-1 knockout (KO) mice, respectively. In order to study the effects of APP and its proteolytic product Aβ on Fragile X syndrome (FXS) phenotypes, we created a novel mouse model (FRAXAD) that over-expresses human APPSwe/Aβ in an fmr-1 KO background. Herein, we assess (1) human APPSwe and Aβ levels as a function of age in FRAXAD mice, and (2) seizure susceptibility to pentylenetetrazol (PTZ) after mGluR5 blockade. PTZ-induced seizure severity is decreased in FRAXAD mice pre-treated with the mGluR5 antagonist MPEP. These data suggest that Aβ contributes to seizure incidence and may be an appropriate therapeutic target to lessen seizure pathology in FXS, Alzheimer's disease (AD) and Down syndrome (DS) patients.

AB - Metabotropic glutamate receptor 5 (mGluR5) regulates the translation of amyloid precursor protein (APP) mRNA. Under resting conditions, mRNA is bound to and translationally repressed by the fragile X mental retardation protein (FMRP). Upon group 1 mGluR activation, FMRP dissociates from the mRNA and translation ensues. APP levels are elevated in the dendrites of primary neuronal cultures as well as in synaptoneurosomes (SN) prepared from embryonic and juvenile fmr-1 knockout (KO) mice, respectively. In order to study the effects of APP and its proteolytic product Aβ on Fragile X syndrome (FXS) phenotypes, we created a novel mouse model (FRAXAD) that over-expresses human APPSwe/Aβ in an fmr-1 KO background. Herein, we assess (1) human APPSwe and Aβ levels as a function of age in FRAXAD mice, and (2) seizure susceptibility to pentylenetetrazol (PTZ) after mGluR5 blockade. PTZ-induced seizure severity is decreased in FRAXAD mice pre-treated with the mGluR5 antagonist MPEP. These data suggest that Aβ contributes to seizure incidence and may be an appropriate therapeutic target to lessen seizure pathology in FXS, Alzheimer's disease (AD) and Down syndrome (DS) patients.

KW - β-amyloid

KW - APP

KW - FMRP

KW - FRAXAD

KW - PTZ

KW - Seizure

KW - Tg2576

UR - http://www.scopus.com/inward/record.url?scp=77449134798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449134798&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 56

EP - 68

JO - International Journal of Clinical and Experimental Pathology

JF - International Journal of Clinical and Experimental Pathology

SN - 1936-2625

IS - 1

ER -